|
CNBC'S MOST SHARED
- CNBC PRESENTS “MEETING OF THE MINDS: THE FUTURE OF HEALTH CARE” ON MONDAY, JULY 27 AT 9PM ET
- New-Home Sales Jump by 11%, Largest Monthly Rise in 9 Years
- Holiday Video Game Lineup Gets Smaller and Smaller
- Power of Social Networking
- How Appraisers Are Threatening Real Estate's Recovery
- Treasury Launches Record Week of Auctions
- Boxers or Briefs-For Your Hands?
- Delphi Board Favors Bid From Bankruptcy Lenders
- Australia Economic Risks Now More Balanced: RBA
- Toyota Eyes 2011 Launch of Hybrid Compact: Report
- SEC Rule on 'Naked' Short-Selling Now Permanent
- Hearings to Consider Limits on Commodity Positions
- GDP to Show Progress, but Recovery Still Uncertain
- Amgen Tops Forecasts, Boosts Outlook; Shares Jump
- Plosser: Fed May Hike Rates Earlier Than Expected
- How Appraisers Are Threatening Real Estate's Recovery
- Nicklaus Paints Bleak Picture On Golf Course Design
- Gortat Won't Be Wearing New Reeboks Next Year
- How Appraisers Are Threatening Real Estate's Recovery
- Best Back-to-School Retail Picks: Analyst
- Boxers or Briefs-For Your Hands?
- Verizon: A 'Tough Business' to Be in Right Now
- Options Action: Mining Exchange Traded Fund
- Making the Case For and Against Healthcare Reform
- Dow 9,000 - Not So Meaningful
Text Size 
A U.S. patent research group says it has uncovered evidence that could be used to declare AstraZeneca's patent for its cholesterol fighter Crestor invalid.
AstraZeneca [AZN-LN Loading... ()] is involved in litigation to defend the Crestor patent from generic drugmakers that want to bring a cheaper copy to the U.S. market.
The patent group, Article One Partners, did not say who found the prior art, essentially information describing the patented technology that dates from before the patent application.
Discovery of good prior art would make defending a patent considerably more difficult.
 |
CNBC.com |
Article One said the person is eligible to win an award of up to $50,000.
A similar discovery by Article One, launched by CEO Cheryl Milone last year, led to a patent office decision last month to reexamine a patent for Merck's [MRK
Loading...
()
] blockbuster Singulair asthma and allergy drug.
Article One encourages researchers and experts in various fields to identify evidence related to patent validity.
Those who succeed are paid and the collected evidence is sold to the group's clients.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes